Skip to main content
All lobbying filings

PERSONALIZED MEDICINE COALITION

Lobbying for PERSONALIZED MEDICINE COALITION · Health care

 Filing 2nd Quarter - Amendment
2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $46,000.00 expenses · posted Mar 5, 2026

Official filing document

 Bills named in this filing 4
  • S 832
    EPIC Act of 2025
  • HR 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • HR 946
    ORPHAN Cures Act
  • HR 1672
    Maintaining Investments in New Innovation Act
 Lobbying activity 2
Health Issues

Congressional Personalized Medicine Caucus S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act House Energy and Commerce Committee Privacy Working Group Request for Information CMS Implementation of Medicare Drug Price Negotiation Program/ Medicare Drug Price Negotiation Program; Draft Guidance for the Medicare Drug Price Negotiation Program: Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026, 2027, and 2028 Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Office of Science and Technology Policy Request for Information on the Development of an Artificial Intelligence (AI) Action Plan Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations [FDA-2024-D-4488] Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products [FDA-2024-D-4689] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community

Budget/Appropriations

FY 2026 Food and Drug Administration Budget Priorities for CDER, CBER and CDRH FY 2026 National Institutes of Health Budget Priorities

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem